NASDAQ:GBT - Global Blood Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $66.20
  • Forecasted Upside: 128.35 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
▲ +1.26 (4.54%)

This chart shows the closing price for GBT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Global Blood Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GBT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GBT

Analyst Price Target is $66.20
▲ +128.35% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Global Blood Therapeutics in the last 3 months. The average price target is $66.20, with a high forecast of $124.00 and a low forecast of $36.00. The average price target represents a 128.35% upside from the last price of $28.99.

This chart shows the closing price for GBT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 investment analysts is to buy stock in Global Blood Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 15 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 15 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 15 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/21/2021SVB LeerinkLower Price TargetOutperform$56.00 ➝ $53.00Low
12/14/2021SVB LeerinkBoost Price TargetOutperform$54.00 ➝ $56.00High
12/7/2021William BlairUpgradeMarket Perform ➝ OutperformHigh
11/5/2021Royal Bank of CanadaLower Price TargetOutperform$66.00 ➝ $64.00High
10/6/2021Jefferies Financial GroupInitiated CoverageBuy$68.00High
9/8/2021WedbushReiterated RatingBuyLow
8/4/2021Truist SecuritiesUpgradeBuy$45.00 ➝ $50.00High
8/4/2021Piper SandlerLower Price TargetNeutral$45.00 ➝ $40.00High
8/4/2021TruistUpgradeHold ➝ Buy$45.00 ➝ $50.00High
6/28/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$70.00 ➝ $36.00High
5/7/2021Cantor FitzgeraldLower Price TargetOverweight$120.00 ➝ $110.00Low
5/6/2021Piper SandlerLower Price Target$50.00 ➝ $45.00High
5/6/2021Roth CapitalLower Price TargetBuy$128.00 ➝ $124.00High
4/14/2021SVB LeerinkInitiated CoverageOutperform$54.00Low
3/11/2021Wolfe ResearchInitiated CoverageOutperform$67.00Low
2/25/2021William BlairDowngradeOutperform ➝ Market PerformHigh
1/20/2021Piper SandlerDowngradeOverweight ➝ Neutral$75.00 ➝ $50.00Low
12/16/2020Morgan StanleyLower Price TargetEqual Weight$67.00 ➝ $45.00Low
12/15/2020HC WainwrightReiterated RatingBuy$75.00Low
12/8/2020William BlairReiterated RatingBuyMedium
12/3/2020Royal Bank of CanadaInitiated CoverageOutperform$75.00High
11/18/2020Cantor FitzgeraldLower Price TargetOverweight$133.00 ➝ $120.00Low
11/9/2020TruistLower Price Target$78.00 ➝ $55.00Low
11/6/2020Morgan StanleyLower Price TargetEqual Weight$68.00 ➝ $67.00High
11/6/2020Roth CapitalLower Price TargetBuy$131.00 ➝ $128.00High
11/6/2020Stifel NicolausLower Price TargetBuy$120.00 ➝ $101.00High
11/6/2020Piper SandlerBoost Price TargetOverweight$75.00 ➝ $120.00High
11/6/2020OppenheimerLower Price TargetOutperform$102.00 ➝ $92.00High
11/6/2020Raymond JamesDowngradeOutperform ➝ Market PerformHigh
10/13/2020Morgan StanleyLower Price TargetEqual Weight$75.00 ➝ $68.00High
10/6/2020Evercore ISIInitiated CoverageOutperform$102.00Medium
8/25/2020WedbushBoost Price Target$145.00 ➝ $152.00Medium
8/24/2020Raymond JamesInitiated CoverageOutperform$115.00Medium
8/6/2020HC WainwrightReiterated RatingBuy$150.00Low
8/6/2020Stifel NicolausBoost Price TargetBuy$113.00 ➝ $118.00High
7/29/2020Piper SandlerReiterated RatingBuy$120.00Low
7/20/2020Roth CapitalInitiated CoverageBuy$129.00Low
7/13/2020Bank of AmericaInitiated CoverageBuy$92.00High
7/1/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$91.00 ➝ $103.00High
6/25/2020HC WainwrightReiterated RatingBuy$150.00Low
6/23/2020WedbushReiterated RatingBuy$145.00High
6/15/2020OppenheimerReiterated RatingBuy$101.00High
6/12/2020Wells Fargo & CompanyReiterated RatingBuyHigh
5/12/2020WedbushReiterated RatingBuy$145.00Low
5/7/2020Cantor FitzgeraldBoost Price Target$105.00 ➝ $130.00Low
5/7/2020NomuraReiterated RatingBuy$112.00Low
5/7/2020Wells Fargo & CompanyBoost Price TargetOverweight$122.00 ➝ $133.00Medium
5/7/2020OppenheimerBoost Price TargetOutperform$88.00 ➝ $101.00Low
5/7/2020Morgan StanleyBoost Price TargetEqual Weight$70.00 ➝ $75.00High
4/27/2020Stifel NicolausInitiated CoverageBuy$112.00Low
4/15/2020Morgan StanleyLower Price TargetEqual Weight$71.00 ➝ $70.00Low
3/19/2020WedbushReiterated RatingBuy$145.00Medium
3/18/2020OppenheimerLower Price Target$100.00 ➝ $88.00Low
3/3/2020Morgan StanleyLower Price TargetEqual Weight$80.00 ➝ $71.00High
1/31/2020SunTrust BanksDowngradeBuy ➝ Hold$110.00 ➝ $75.00High
1/17/2020Morgan StanleyBoost Price TargetEqual Weight$79.00 ➝ $80.00Medium
12/23/2019Piper Jaffray CompaniesReiterated RatingBuy$120.00N/A
12/22/2019WedbushReiterated RatingBuy$143.00Medium
12/18/2019William BlairReiterated RatingBuyHigh
12/17/2019JPMorgan Chase & Co.Boost Price TargetEqual Weight$58.00 ➝ $79.00Low
12/10/2019Piper Jaffray CompaniesBoost Price Target$95.00 ➝ $120.00High
12/9/2019OppenheimerReiterated RatingBuy$100.00Low
11/26/2019Nomura SecuritiesBoost Price TargetBuy$109.00 ➝ $112.00High
11/26/2019WedbushReiterated RatingBuy$143.00High
11/26/2019Janney Montgomery ScottBoost Price TargetBuy$75.00 ➝ $90.00High
11/26/2019SunTrust BanksBoost Price TargetBuy$110.00High
11/26/2019Piper Jaffray CompaniesBoost Price TargetOverweight$80.00 ➝ $95.00High
11/25/2019Cantor FitzgeraldReiterated RatingBuy$110.00 ➝ $98.00High
10/17/2019Cantor FitzgeraldReiterated RatingOverweightHigh
10/14/2019SunTrust BanksBoost Price TargetBuy$100.00Low
10/9/2019CowenSet Price TargetBuy$83.00Low
10/9/2019WedbushReiterated RatingBuy$120.00Low
10/9/2019Wells Fargo & CompanyBoost Price TargetOutperform$96.00 ➝ $104.00Medium
10/9/2019HC WainwrightReiterated RatingBuy$150.00Medium
10/8/2019William BlairReiterated RatingBuyLow
9/12/2019WedbushReiterated RatingBuy$120.00Medium
9/6/2019HC WainwrightSet Price TargetBuy$150.00Low
9/5/2019CowenSet Price TargetBuy$83.00Low
9/5/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
9/5/2019WedbushBoost Price TargetOutperform ➝ Hold$103.00 ➝ $120.00High
8/12/2019WedbushReiterated RatingOutperform$103.00Low
8/11/2019JPMorgan Chase & Co.Reiterated RatingBuy$75.00Low
8/9/2019Morgan StanleySet Price TargetHold$60.00Medium
8/8/2019CowenReiterated RatingBuy$83.00Low
8/8/2019HC WainwrightReiterated RatingBuy$150.00Low
6/28/2019WedbushSet Price TargetBuy$103.00Medium
6/25/2019HC WainwrightReiterated RatingBuyLow
6/17/2019WedbushReiterated RatingBuy$107.00Medium
6/16/2019CowenReiterated RatingBuyMedium
6/14/2019Cantor FitzgeraldSet Price TargetBuy$96.00 ➝ $110.00High
6/11/2019WedbushReiterated RatingBuy$107.00Low
6/3/2019WedbushReiterated RatingBuy$95.00 ➝ $107.00High
5/29/2019The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$75.00Low
5/13/2019WedbushReiterated RatingBuy$95.00High
5/9/2019OppenheimerBoost Price TargetOutperform$82.00 ➝ $89.00Medium
4/18/2019WedbushReiterated RatingOutperform$95.00Medium
4/12/2019HC WainwrightSet Price TargetBuy$150.00High
4/1/2019Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $96.00Low
3/5/2019WedbushBoost Price TargetOutperform ➝ Outperform$91.00 ➝ $95.00Low
3/4/2019Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$55.00 ➝ $57.00Low
2/28/2019JPMorgan Chase & Co.Reiterated RatingBuy$75.00Low
2/22/2019GuggenheimInitiated CoverageBuy$75.00Low
1/30/2019William BlairReiterated RatingBuyHigh
12/19/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$54.00 ➝ $55.00High
12/4/2018SunTrust BanksBoost Price TargetBuy ➝ Positive$90.00Medium
12/4/2018HC WainwrightSet Price TargetBuy$150.00Medium
12/3/2018William BlairReiterated RatingBuyHigh
12/3/2018Cantor FitzgeraldSet Price TargetBuy$96.00High
12/3/2018OppenheimerSet Price TargetBuy$82.00High
11/28/2018HC WainwrightReiterated RatingBuy ➝ Buy$150.00High
11/19/2018WedbushReiterated RatingBuy$73.00Low
11/7/2018OppenheimerSet Price TargetBuy$74.00 ➝ $82.00High
11/7/2018William BlairReiterated RatingBuyHigh
11/5/2018HC WainwrightSet Price TargetBuy$125.00Low
11/1/2018OppenheimerSet Price TargetBuy$74.00Medium
10/23/2018Cantor FitzgeraldSet Price TargetBuy$96.00Low
10/19/2018HC WainwrightSet Price TargetBuy$125.00High
10/18/2018William BlairReiterated RatingBuyHigh
10/17/2018Cantor FitzgeraldReiterated RatingBuy$96.00High
10/2/2018Cantor FitzgeraldSet Price TargetBuy$96.00High
9/13/2018HC WainwrightSet Price TargetBuy$125.00High
8/23/2018Cantor FitzgeraldSet Price TargetBuy$96.00Medium
8/23/2018HC WainwrightSet Price TargetBuy$125.00Low
8/13/2018CowenReiterated RatingBuy$83.00High
8/8/2018HC WainwrightSet Price TargetBuy$125.00Low
8/8/2018Cantor FitzgeraldReiterated RatingBuy$96.00Low
8/6/2018WedbushReiterated RatingOutperform ➝ Outperform$73.00Low
8/6/2018Piper Jaffray CompaniesInitiated CoverageOverweight$80.00Low
8/5/2018SunTrust BanksSet Price TargetBuy$70.00Low
8/5/2018JPMorgan Chase & Co.Reiterated RatingBuy$75.00Low
8/2/2018Cantor FitzgeraldReiterated RatingBuy$96.00High
7/27/2018HC WainwrightReiterated RatingBuy$125.00High
6/28/2018Nomura SecuritiesBoost Price TargetBuy ➝ Buy$91.00 ➝ $109.00High
6/27/2018HC WainwrightBoost Price TargetBuy ➝ Buy$73.00 ➝ $125.00High
6/27/2018Wells Fargo & CompanyBoost Price TargetOutperform$78.00 ➝ $85.00High
6/27/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$69.00 ➝ $96.00High
6/18/2018WedbushReiterated RatingOutperform$70.00Low
5/24/2018HC WainwrightSet Price TargetBuy$73.00Low
5/21/2018WedbushReiterated RatingOutperform$70.00High
5/10/2018HC WainwrightSet Price TargetBuy$73.00Medium
5/9/2018Cantor FitzgeraldSet Price TargetBuy$69.00Medium
5/8/2018SunTrust BanksLower Price TargetBuy ➝ Buy$80.00 ➝ $77.00High
5/8/2018OppenheimerLower Price TargetOutperform ➝ Outperform$79.00 ➝ $74.00High
4/26/2018Needham & Company LLCReiterated RatingBuy$70.00High
3/21/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$61.00High
3/14/2018WedbushReiterated RatingOutperform$73.00Low
3/12/2018HC WainwrightSet Price TargetBuy$73.00High
3/6/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$58.00 ➝ $61.00Low
3/1/2018SunTrust BanksSet Price TargetPositive ➝ Buy$80.00Medium
2/28/2018William BlairReiterated RatingBuyHigh
2/28/2018HC WainwrightSet Price TargetBuy$73.00High
2/27/2018Cantor FitzgeraldSet Price TargetOverweight ➝ Overweight$61.00 ➝ $72.00High
2/13/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$75.00Medium
1/23/2018William BlairInitiated CoverageOutperform ➝ Outperform$80.00High
1/11/2018HC WainwrightSet Price TargetBuy$73.00Medium
12/15/2017WedbushReiterated RatingOutperform$73.00Low
12/14/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$51.00 ➝ $70.00Low
12/12/2017OppenheimerSet Price TargetBuy$53.00 ➝ $79.00High
12/11/2017Nomura SecuritiesBoost Price TargetBuy$91.00High
12/11/2017HC WainwrightSet Price TargetBuy$73.00High
12/11/2017Cantor FitzgeraldSet Price TargetBuy$61.00High
12/4/2017WedbushReiterated RatingOutperform$73.00High
12/1/2017HC WainwrightInitiated CoverageBuy$73.00High
11/13/2017OppenheimerSet Price TargetBuy$53.00N/A
11/9/2017CowenReiterated RatingBuy$83.00N/A
11/6/2017SunTrust BanksBoost Price TargetBuy$67.00N/A
10/30/2017OppenheimerSet Price TargetBuy$53.00N/A
10/24/2017Needham & Company LLCSet Price TargetBuy$51.00N/A
10/23/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
10/23/2017OppenheimerSet Price TargetBuy$53.00N/A
10/18/2017Needham & Company LLCSet Price TargetBuy$51.00N/A
10/11/2017OppenheimerSet Price TargetBuy$53.00N/A
10/6/2017Morgan StanleyReiterated RatingOverweight$51.00 ➝ $56.00N/A
9/20/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$51.00High
9/18/2017WedbushReiterated RatingOurperform$73.00Medium
8/14/2017CowenReiterated RatingOutperform$83.00Medium
8/8/2017JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$44.00 ➝ $46.00Medium
8/4/2017OppenheimerInitiated CoverageOutperform$53.00High
7/11/2017Morgan StanleyReiterated RatingOverweightLow
5/2/2017WedbushReiterated RatingOutperform$73.00High
5/1/2017Janney Montgomery ScottInitiated CoverageBuy$37.00Low
4/17/2017SunTrust BanksInitiated CoverageBuy ➝ Buy$56.00High
3/20/2017Roth CapitalSet Price TargetBuy$47.00Low
3/20/2017WedbushReiterated RatingOutperform ➝ Outperform$73.00Low
3/15/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$61.00Low
3/15/2017JPMorgan Chase & Co.Reiterated RatingBuy$44.00Medium
3/1/2017Nomura InstinetInitiated CoverageBuy ➝ Buy$50.00N/A
3/1/2017Nomura SecuritiesInitiated CoverageBuyN/A
2/18/2017Roth CapitalSet Price TargetBuy$47.00N/A
(Data available from 1/17/2017 forward)

News Sentiment Rating

0.65 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 8 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 5 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 5 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Global Blood Therapeutics logo
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $28.99
Low: $27.14
High: $29.13

50 Day Range

MA: $29.96
Low: $24.90
High: $33.87

52 Week Range

Now: $28.99
Low: $24.61
High: $52.49


1,122,121 shs

Average Volume

1,190,240 shs

Market Capitalization

$1.87 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Global Blood Therapeutics?

The following sell-side analysts have issued reports on Global Blood Therapeutics in the last twelve months: Cantor Fitzgerald, Jefferies Financial Group Inc., JPMorgan Chase & Co., Piper Sandler, Roth Capital, Royal Bank of Canada, SVB Leerink LLC, Truist, Truist Securities, Wedbush, William Blair, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for GBT.

What is the current price target for Global Blood Therapeutics?

10 Wall Street analysts have set twelve-month price targets for Global Blood Therapeutics in the last year. Their average twelve-month price target is $66.20, suggesting a possible upside of 128.4%. Roth Capital has the highest price target set, predicting GBT will reach $124.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $36.00 for Global Blood Therapeutics in the next year.
View the latest price targets for GBT.

What is the current consensus analyst rating for Global Blood Therapeutics?

Global Blood Therapeutics currently has 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GBT will outperform the market and that investors should add to their positions of Global Blood Therapeutics.
View the latest ratings for GBT.

What other companies compete with Global Blood Therapeutics?

How do I contact Global Blood Therapeutics' investor relations team?

Global Blood Therapeutics' physical mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 741-7700 and its investor relations email address is [email protected] The official website for Global Blood Therapeutics is